President Donald Trump signed an executive order Saturday in the Oval Office directing his administration to speed access to medical research and treatments based on psychedelic drugs, a move aimed squarely at veterans suffering from PTSD, traumatic brain injuries, addiction, and depression. Podcaster Joe Rogan stood at his side for the signing, having personally pushed the president to act on the issue.
The order, titled “Accelerating Medical Treatments for Serious Mental Illness,” marshals the FDA, the Department of Health and Human Services, the VA, and the NIH toward a single goal: clearing bureaucratic barriers that have kept promising psychedelic compounds, particularly ibogaine, locked behind decades of Schedule I restrictions and sluggish federal review processes.
Flanking Trump during the signing were HHS Secretary Robert F. Kennedy Jr., Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz, and FDA Commissioner Marty Makary. NIH Director Jay Bhattacharya was also named by the president as part of the team he ordered to move on the initiative, as Breitbart reported.
The order directs the FDA to expedite review of psychedelic drugs already designated as breakthrough therapies. It calls for priority review vouchers for three psychedelics, a tool that could compress review timelines from months to weeks. And it instructs HHS to direct at least $50 million to states developing programs for psychedelic drugs aimed at serious mental illness, AP News reported.
Trump also said the federal government would invest $50 million in ibogaine research specifically and open a pathway for ibogaine use under the right-to-try law. The order removes legal restrictions that have limited extensive study of ibogaine, which remains classified as a Schedule I controlled substance in the United States.
The FDA is also taking steps toward the first human trials of ibogaine on American soil, Newsmax reported, and the order establishes FDA protocols for safe therapeutic use of psychedelics while improving data sharing between the FDA and the Department of Veterans Affairs.
Trump framed the action as a matter of urgency, not ideology. In remarks at the signing, he said:
“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life.”
He added a line that captured the administration’s impatience with the federal approval pipeline: “If these turn out to be as good as people are saying, it’s going to have a tremendous impact.”
Rogan’s presence in the Oval Office was not ceremonial. Trump referred to him as “the great Joe Rogan” and credited him, along with others, for bringing the issue to his attention. Rogan told the room he had texted the president about ibogaine and studies he says show over 80 percent of people addicted to opioids who take one dose of ibogaine “are free of that addiction.”
Rogan described the exchange in blunt terms:
“I sent him that information. The text message that came back: ‘Sounds great. Do you want FDA approval? Let’s do it.’ Literally that quick.”
Trump echoed that account, saying the support he found when he asked his team was unanimous.
“It was uniform support, and I said, ‘So why would we wait three or four years to get it done or ten years, frankly? Let’s get it done immediately.’ And that’s what happened.”
The president’s willingness to act on a direct text from a podcaster will draw scrutiny from some quarters. But the substance of the order, accelerating research for veterans in crisis, is hard to argue against on the merits. This is an administration that has shown it will move fast on policy changes when it sees an opening, and the psychedelics order fits that pattern.
Trump made clear the order’s primary justification is the ongoing epidemic of veteran suicides. He stated plainly:
“Everybody is so strongly in favor of this. It’s for a lot of people, but it’s for our military in particular. The suicide epidemic among veterans is a national tragedy.”
That framing has drawn bipartisan and veteran-backed support. Veterans groups, Marcus Luttrell, and former Texas Governor Rick Perry have all helped build the case for easing restrictions on ibogaine research and access, Newsmax noted. The coalition behind this order is broader than the usual partisan lines suggest.
Dr. Mehmet Oz, speaking at the signing, called the approach a fundamental change in how the government thinks about mental health treatment. As the New York Post reported, Oz said: “This is an entire paradigm shift away from a one-day-a-pill model, which has failed so many.”
That line lands harder than most policy rhetoric. For years, the standard federal approach to veteran mental health has leaned on SSRIs and conventional psychiatric drugs, treatments that help some patients but leave many others cycling through prescriptions without relief. The administration is betting that psychedelic-assisted therapy, particularly with ibogaine, can break that cycle.
Ibogaine is the compound at the center of this executive order, and it carries both extraordinary claims and real medical concerns. Rogan cited studies suggesting a single dose can free more than 80 percent of opioid-addicted patients from their dependency. That figure, if validated through rigorous clinical trials, would represent a breakthrough unlike anything in modern addiction medicine.
But ibogaine is not without danger. AP News noted that the drug carries serious heart-related safety risks, a fact the administration has not disputed. The order’s emphasis on establishing FDA safety protocols and conducting the first U.S. human trials suggests the White House is aware that enthusiasm must be paired with clinical rigor.
Rogan also waded into the political history of drug scheduling, arguing that psychedelics “are illegal not because they’re harmful” but because the Controlled Substances Act of 1970 was designed to “target” the Civil Rights and anti-war movements. That claim is Rogan’s own characterization, and it will be debated. But the practical point, that Schedule I classification has frozen research for over fifty years, is harder to dismiss.
The Washington Times reported that the order also calls for fast rescheduling of any psychedelic drugs that become FDA-approved, which would remove one of the largest remaining barriers to widespread clinical use. Trump himself said the order “will clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA and the Department of Veterans Affairs, and facilitate fast rescheduling of any psychedelic drugs that become FDA-approved.”
This executive order stands apart from the typical culture-war flashpoints that dominate coverage of the Trump administration. It is not a border action, not a tariff, not a legal battle. It is a health-policy move with genuine bipartisan appeal, driven by a coalition that includes a libertarian-leaning podcaster, a Kennedy, a former reality-TV doctor, and combat veterans.
The administration has been willing to use executive power aggressively across a wide range of issues, from imposing tariffs on nations arming Iran to making history by attending Supreme Court oral arguments on birthright citizenship. The psychedelics order is a quieter use of that same executive muscle, but it may prove to be one of the most consequential.
The New York Post reported that government-sanctioned treatments could begin as soon as this summer if authorized, which would mark an extraordinarily compressed timeline from executive order to clinical access.
Open questions remain. The specific provisions of the executive order beyond its title and stated purpose have not been fully detailed in public reporting. The studies Rogan referenced about ibogaine’s efficacy have not been identified by name. And whether the quoted text exchange between Rogan and Trump was reproduced from a device or recounted from memory is unclear.
None of that changes the central fact: the federal government, for the first time, is putting real institutional weight behind psychedelic medicine for veterans and the seriously mentally ill. The FDA, HHS, NIH, and VA have all been directed to act, not to study whether to study, but to move.
For decades, Washington’s answer to the veteran suicide crisis has been more funding for the same approaches that weren’t working. This order, whatever its risks, at least has the honesty to try something different.
By signing up, you agree to receive our newsletters and promotional content and accept our Terms of Use and Privacy Policy. You may unsubscribe at any time.